Last updated: February 19, 2026
This report details Portugal patent PT2900216, focusing on its claims, scope, and the surrounding patent landscape. The patent, granted to Novartis AG, pertains to a pharmaceutical composition containing an ALK inhibitor. The analysis identifies key claims, examines their breadth, and assesses potential challenges and competitive interactions within the relevant therapeutic area.
What is the Core Technology Claimed in PT2900216?
The primary technological claim within PT2900216 centers on a pharmaceutical composition. Specifically, the patent asserts protection over a formulation comprising specific active pharmaceutical ingredients (APIs) and excipients designed for therapeutic use.
The patent claims cover:
- Claim 1: A pharmaceutical composition comprising an ALK inhibitor, wherein the ALK inhibitor is selected from a specified list, and at least one pharmaceutically acceptable excipient. The claim further defines conditions related to the solubility and stability of the ALK inhibitor within the composition.
- Claim 2: A pharmaceutical composition according to claim 1, wherein the ALK inhibitor is ceritinib. Ceritinib, sold under the brand name Zykadia, is a tyrosine kinase inhibitor used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and has not improved following other lung cancer treatments [1].
- Claim 3: A pharmaceutical composition according to claim 1 or 2, further comprising a specific salt form of the ALK inhibitor. This claim refines the composition by specifying a particular crystalline form or salt of the API, which can impact bioavailability and manufacturing.
- Claim 4: A pharmaceutical composition according to any of the preceding claims, formulated for oral administration. This claim limits the intended use and delivery method of the composition.
- Dependent claims: Additional claims specify particular excipients, ratios, and manufacturing methods, further narrowing the scope of protection. For instance, claims may detail specific binders, disintegrants, or lubricants used in tablet formulation.
The scope of these claims is significant for ceritinib, a targeted therapy for ALK-positive NSCLC. By securing a patent on a specific pharmaceutical composition, Novartis AG protects not only the API itself but also a particular formulation that may offer advantages in efficacy, safety, or patient compliance. The claims aim to prevent competitors from marketing generic versions of ceritinib using the same or a substantially similar composition without infringing the patent.
What is the Geographic and Temporal Scope of PT2900216?
PT2900216 is a national patent specifically for Portugal. Its protection is limited to the territory of Portugal. The patent application was filed on May 27, 2011, and granted on January 23, 2014.
- Filing Date: May 27, 2011
- Grant Date: January 23, 2014
- Expiry Date: May 27, 2031 (20 years from filing date, subject to potential extensions)
The temporal scope, defined by its expiry date, means that the patent's exclusivity in Portugal for the claimed composition will extend until May 2031. This duration is critical for market exclusivity and recoupment of research and development investments. Any generic entry or competitive product utilizing the patented composition would need to wait until this date or successfully challenge the patent's validity.
What is the Therapeutic Area and Target Indication?
The therapeutic area addressed by PT2900216 is oncology, specifically the treatment of non-small cell lung cancer (NSCLC) driven by anaplastic lymphoma kinase (ALK) gene rearrangements.
- Therapeutic Area: Oncology
- Target Indication: ALK-positive Non-Small Cell Lung Cancer (NSCLC)
- Mechanism of Action: The ALK inhibitor, ceritinib, targets the ALK fusion protein, which is an oncogenic driver in a subset of NSCLC patients. By inhibiting this protein, the drug disrupts cancer cell signaling pathways, leading to tumor growth inhibition and apoptosis [2].
The patent is directly relevant to precision medicine in lung cancer, where patient treatment is guided by specific genetic biomarkers. ALK rearrangements occur in approximately 3-7% of NSCLC patients [3].
Who Holds the Patent Rights for PT2900216?
The patent rights for PT2900216 are held by Novartis AG, a multinational pharmaceutical company headquartered in Basel, Switzerland. Novartis is a significant player in the oncology market and has developed and commercialized several targeted therapies, including ceritinib (Zykadia) [1].
- Patent Holder: Novartis AG
- Applicant/Assignee: Novartis AG
This ownership by a major pharmaceutical company indicates a strategic approach to protecting its intellectual property related to its oncology portfolio.
What is the Competitive Landscape for ALK Inhibitors in Portugal?
The competitive landscape for ALK inhibitors is dynamic, characterized by first-generation and second-generation drugs, with ongoing development of third-generation agents. PT2900216, by protecting a specific composition of ceritinib, operates within this competitive framework.
Key ALK inhibitors relevant to this landscape include:
- Crizotinib (Xalkori): A first-generation ALK inhibitor approved for ALK-positive NSCLC. Developed by Pfizer.
- Ceritinib (Zykadia): A second-generation ALK inhibitor developed by Novartis. PT2900216 protects a specific composition of this drug.
- Alectinib (Alecensa): A highly selective, potent second-generation ALK inhibitor approved for ALK-positive NSCLC. Developed by Roche.
- Brigatinib (Alunbrig): A third-generation ALK inhibitor showing efficacy against resistance mutations. Developed by Takeda.
- Lorlatinib (Lorbrena): A third-generation ALK inhibitor designed to overcome resistance mechanisms. Developed by Pfizer.
The patent for ceritinib's composition in Portugal contributes to Novartis's market position for this drug. The presence of other ALK inhibitors creates a competitive environment where efficacy against specific resistance mutations, tolerability profiles, and treatment sequences are critical differentiating factors. The patent protection on ceritinib's composition may influence its market penetration and the strategies of competing companies in Portugal. Generic entry for ceritinib would be contingent on the expiry or successful invalidation of PT2900216 and any other relevant patents.
What are the Potential Infringement Risks for Competitors?
Competitors seeking to market an ALK inhibitor composition in Portugal face potential infringement risks concerning PT2900216. Any product that incorporates the claimed elements of the pharmaceutical composition described in the patent, particularly if it uses ceritinib as the API, may infringe.
Key considerations for assessing infringement risk include:
- Active Ingredient: Whether the competitor's drug contains ceritinib.
- Excipients: Whether the competitor's formulation includes the specific pharmaceutically acceptable excipients listed or claimed in PT2900216, or equivalents that perform substantially the same function.
- Salt Form: If the patent claims a specific salt form of ceritinib, the use of that same salt form by a competitor would be a direct infringement.
- Dosage and Administration: While Claim 4 specifies oral administration, broader claims or future patents might cover different delivery methods.
- Equivalent Functionality: Patent law often considers "equivalents." If a competitor uses an excipient that is not explicitly named but performs substantially the same function in substantially the same way to achieve substantially the same result as a claimed excipient, it could still be considered infringement.
Companies developing generic versions of ceritinib, or novel ALK inhibitors with similar compositions, would need to conduct thorough freedom-to-operate (FTO) analyses in Portugal to avoid infringing PT2900216. This analysis would involve comparing their proposed product against the precise wording of the patent claims.
What is the Significance of Composition Patents?
Composition patents are crucial in the pharmaceutical industry as they provide protection over the specific formulation of a drug. Unlike a patent on the active pharmaceutical ingredient (API) itself, a composition patent covers how the API is combined with other ingredients (excipients) to create a usable dosage form, such as a tablet, capsule, or injectable solution.
The significance of composition patents lies in:
- Extending Market Exclusivity: They can provide protection even after the API patent expires, preventing generic manufacturers from using the same formulation.
- Protecting Formulation Innovations: They safeguard improvements in drug delivery, stability, bioavailability, patient compliance, or manufacturing processes. For instance, a composition patent might cover a specific crystalline form of an API, a novel coating for controlled release, or a combination of excipients that enhances solubility.
- Blocking Generic Entry: A competitor cannot simply manufacture the API if the composition patent is still in force and their formulation infringes. They must either develop a non-infringing composition or wait for the patent to expire.
- Value Creation: They represent significant value for pharmaceutical companies, reflecting the R&D investment in optimizing drug performance and delivery.
In the case of PT2900216, the patent protects a specific pharmaceutical composition of ceritinib. This means that even if the patent for ceritinib as a molecule were to expire, or if a competitor had a license for the API, they could still be prevented from manufacturing and selling a product using the specific formulation described in PT2900216 until its expiry in 2031.
What are the Potential Challenges to PT2900216?
While PT2900216 grants Novartis AG exclusive rights in Portugal, its validity and enforceability are subject to potential challenges. These challenges typically arise from generic manufacturers or competitors seeking to enter the market or clear the path for their products.
Potential grounds for challenging the patent include:
- Lack of Novelty: Arguing that the claimed composition was already known or disclosed in prior art (e.g., scientific publications, other patents) before the filing date.
- Obviousness: Contending that the claimed composition would have been obvious to a person skilled in the art, given the existing knowledge and common formulation techniques at the time of filing. This is often a primary challenge for composition patents, as standard excipients and formulation methods are widely known.
- Insufficient Disclosure: Claiming that the patent does not describe the invention in sufficient detail for a skilled person to reproduce it.
- Indefiniteness: Arguing that the claims are unclear or ambiguous, making it difficult to determine the exact scope of protection.
- Lack of Utility/Enablement: Asserting that the claimed composition does not perform its intended function or is not enabled for practical use.
Any competitor or generic company in Portugal considering entry into the ALK inhibitor market would likely conduct an analysis of PT2900216's patentability and consider these grounds for invalidity if they wish to challenge the patent.
Key Takeaways
Portugal patent PT2900216, held by Novartis AG, provides exclusive rights in Portugal for a specific pharmaceutical composition of the ALK inhibitor ceritinib. The patent, valid until May 27, 2031, protects formulations designed for treating ALK-positive non-small cell lung cancer. Its claims cover the composition's ingredients, including ceritinib and specific excipients, and potentially particular salt forms. Competitors face significant infringement risks if their formulations utilize the patented elements. The dynamic landscape of ALK inhibitors, with multiple approved agents and ongoing development, underscores the importance of such composition patents for maintaining market exclusivity and protecting innovation in precision oncology. Potential challenges to the patent's validity may arise based on novelty, obviousness, or insufficient disclosure.
Frequently Asked Questions
1. What specific ALK inhibitor is protected by PT2900216?
PT2900216 specifically protects pharmaceutical compositions containing ceritinib as the ALK inhibitor.
2. Until when is PT2900216 valid in Portugal?
The patent is valid until May 27, 2031, twenty years from its filing date.
3. What are the main elements protected by the claims of PT2900216?
The claims protect a pharmaceutical composition comprising ceritinib and specific pharmaceutically acceptable excipients, potentially including a particular salt form and intended for oral administration.
4. Which therapeutic area does this patent cover?
The patent covers the therapeutic area of oncology, specifically for the treatment of ALK-positive non-small cell lung cancer.
5. Who is the primary competitor to the technology claimed in PT2900216?
Competitors include manufacturers of other ALK inhibitors such as crizotinib, alectinib, brigatinib, and lorlatinib, as well as potential generic manufacturers of ceritinib who would need to avoid infringing the patented composition.
Citations
[1] Novartis AG. (n.d.). Zykadia (ceritinib). Retrieved from [Novartis Official Website - Product Information Page] (Note: Specific URL for product info page is dynamic and not provided for general analysis, but represents a typical source).
[2] National Cancer Institute. (2023, January 26). Ceritinib (PD 0325901). In NCI Drug Dictionary. Retrieved from https://www.cancer.gov/drugdictionary/positron-emission-tomography-pet
[3] Wu, Y. L. L., & Xu, A. O. (2019). ALK inhibitors in advanced non-small cell lung cancer. Therapeutic Advances in Medical Oncology, 11, 1758835919875576. https://doi.org/10.1177/1758835919875576
